Business
908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook
BOSTON, May 13, 2025--908 Devices Inc. (Nasdaq: MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025.
About this update from 908 Devices Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4743,"height":1356,"url":"https://media.zenfs.com/en/business-wire.com/2ba8086e7890a3412d56c6c1f06eece3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7IZevvFRCRtI9FQROxxgzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2ba8086e7890a3412d56c6c1f06eece3","width":960,"height":274},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_MU1lnzZOcNxk.1dX9yeSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02ODY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2ba8086e7890a3412d56c6c1f06eece3","width":1200,"height":343}},"lazy":false},{"type":"text","content":"Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 13, 2025--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025.","length":287,"tagName":"p"},{"type":"text","content":""We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends increasingly developing into tailwinds, we remain fully committed to our adjusted EBITDA profitability target by the fourth quarter and expanding our leadership in frontline chemical detection."","length":540,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced divestiture of bioprocessing product portfolio to Repligen Corporation on March 4th","length":93,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Total revenue was $11.8 million for the first quarter 2025, increasing 59% year over year, driven by $11.0 million in handheld product and service revenue, which grew 86% compared to the prior year period","length":204,"ta...